SILDENAFIL CITRATE
- Product NDC
- 60290-003
- Requested package NDC
- 60290-003-03
- 11-digit product format
- 602900003
- Labeler code
- 60290
- Product ID
- 60290-003_51b76a30-43fd-eaa4-e063-6394a90a286d
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- SILDENAFIL CITRATE
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Umedica Laboratories USA Inc.
- Application
- ANDA209302
- Marketing category
- ANDA
- Marketing start
- 2026-02-15
- Substance
- SILDENAFIL CITRATE
- Active strength
- 100 mg/1
- Pharmacologic classes
- Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209302-001 | SILDENAFIL CITRATE | SILDENAFIL CITRATE | EQ 50MG BASE | TABLET / ORAL | AB | 2020-08-25 | |
| A209302-002 | SILDENAFIL CITRATE | SILDENAFIL CITRATE | EQ 100MG BASE | TABLET / ORAL | AB | 2020-08-25 | |
| A209302-003 | SILDENAFIL CITRATE | SILDENAFIL CITRATE | EQ 25MG BASE | TABLET / ORAL | AB | 2021-06-15 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209302-001 | AB |
| A209302-002 | AB |
| A209302-003 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209302-001 | SILDENAFIL CITRATE | EQ 50MG BASE | TABLET / ORAL | AB | 2020-08-25 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209302-002 | SILDENAFIL CITRATE | EQ 100MG BASE | TABLET / ORAL | AB | 2020-08-25 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209302-003 | SILDENAFIL CITRATE | EQ 25MG BASE | TABLET / ORAL | AB | 2021-06-15 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209302-001 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209302-002 | AB | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209302-003 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | PD-Rx Pharmaceuticals, Inc. | 00ee09dd-2de0-4dc4-85f6-b51ed6eabd5b | 2026-07-29 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | PD-Rx Pharmaceuticals, Inc. | f1122baa-8dee-43fc-bd3d-501a55b696b3 | 2026-07-29 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Umedica Laboratories USA Inc. | 90477a51-63ba-43f4-a74b-4659a946093c | 2026-05-13 | Warnings, Adverse reactions | 209302 ANDA209302 60290-003-03 60290-003 60290000303 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | NIVAGEN PHARMACEUTICALS, INC. | 5ac95dd0-57e4-495c-bf8d-b2e5bbe33e20 | 2026-04-27 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Northstar Rx LLC | 8127ff38-2761-49ec-8ce7-7f971f521cfb | 2026-02-26 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Proficient Rx LP | 8780c159-8b61-402b-afbe-64f5c85d3886 | 2025-11-01 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Proficient Rx LP | 30ce6e7f-716e-4a68-a4fb-2bb2d34ed052 | 2025-11-01 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Proficient Rx LP | 1add0cab-8873-4cd1-ab53-e05c4ac458b1 | 2025-10-01 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | PD-Rx Pharmaceuticals, Inc. | dc4430cc-8238-4d6d-99ff-bbb9d0b51bd1 | 2025-04-04 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Advanced Rx of Tennessee, LLC | 30cb7d6a-ce40-c794-e063-6294a90a6861 | 2025-03-20 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Preferred Pharmaceuticals Inc. | 5846bff2-6a93-46a7-a547-04459c590814 | 2025-01-20 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | A-S Medication Solutions | 6d79946b-72a9-4d1b-a84b-9d1a679a82e2 | 2024-06-18 | Warnings, Adverse reactions | 209302 ANDA209302 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | Proficient Rx LP | 59b623bc-fbdd-4f32-8327-0d600763f429 | 2022-11-01 | Warnings, Adverse reactions | 209302 ANDA209302 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- SILDENAFIL CITRATE
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| SILDENAFIL CITRATE | 100 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| BW9B0ZE037 | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 90477a51-63ba-43f4-a74b-4659a946093c | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| fabccea2-36c8-9268-ee44-ec231455538f | Product name | 9 | 20241217 |
| ac996ae9-22a2-41c2-bb86-913c4aef95ad | Product name | 1 | 20230606 |
| fc95c9f0-00dc-40ef-bcea-b60c9009c5fc | Product name | 9 | 20220613 |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 60290-003-01 | SILDENAFIL CITRATE | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 4 | |
| 60290-003-02 | SILDENAFIL CITRATE | 100 in 1 BOTTLE | TABLET, FILM COATED | 100 | 4 | |
| 60290-003-03 | SILDENAFIL CITRATE | 1000 in 1 BOTTLE | TABLET, FILM COATED | 1000 | 4 | |
| 60290-003-04 | SILDENAFIL CITRATE | 500 in 1 BOTTLE | TABLET, FILM COATED | 500 | 4 | |
| 60290-003-05 | SILDENAFIL CITRATE | 4000 in 1 BOTTLE | TABLET, FILM COATED | 4000 | 4 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 314229 | sildenafil citrate 100 MG Oral Tablet | PSN | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 314228 | sildenafil citrate 25 MG Oral Tablet | PSN | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 312950 | sildenafil citrate 50 MG Oral Tablet | PSN | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 314229 | sildenafil 100 MG Oral Tablet | SCD | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 314228 | sildenafil 25 MG Oral Tablet | SCD | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 312950 | sildenafil 50 MG Oral Tablet | SCD | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 314229 | sildenafil 100 MG (as sildenafil citrate) Oral Tablet | SY | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 314228 | sildenafil 25 MG (as sildenafil citrate) Oral Tablet | SY | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
| 312950 | sildenafil 50 MG (as sildenafil citrate) Oral Tablet | SY | 90477a51-63ba-43f4-a74b-4659a946093c | 4 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 60290-003-03 | 60290000303 | 1000 TABLET, FILM COATED in 1 BOTTLE (60290-003-03) | 2026-02-15 | No | No | Current |